Axsome Therapeutics (AXSM)CEO sold ~$2.25M
Herriot Tabuteau, CEO at Axsome Therapeutics, sold ~$2.25M of Axsome Therapeutics shares.
- ~$2.25M
- Approx. value · 20K sh @ $114.19
- 7,229
- Holds after · shares reported
- Traded
- Sep 16, 2025
- Filed
- Sep 16, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Aug 22, 2025InsiderDirector sold ~$2M of AXSM shares in the open market
- Aug 26, 2025InsiderDirector sold ~$2.4M of AXSM shares in the open market
- Aug 27, 2025InsiderDirector sold ~$2.45M of AXSM shares in the open market
- Aug 28, 2025InsiderDirector sold ~$2.43M of AXSM shares in the open market
- Aug 29, 2025InsiderDirector sold ~$2.43M of AXSM shares in the open market
- Sep 2, 2025InsiderDirector sold ~$1.67M of AXSM shares in the open market
- Sep 5, 2025InsiderDirector sold ~$1.14M of AXSM shares in the open market
- Sep 8, 2025Insider · 1 personInsiders: 3 purchases (~$200K)
- Sep 12, 2025InsiderCEO sold ~$3.32M of AXSM shares in the open market
- Sep 15, 2025InsiderCEO sold ~$1.79M of AXSM shares in the open market
- Sep 16, 2025 · this disclosureInsiderCEO sold ~$2.25M of AXSM shares in the open market
What came next
- Sep 16, 2025Insider · 1 personInsiders: 2 sales (~$5.2M)
- Sep 22, 2025InsiderOfficer sold ~$1.16M of AXSM shares in the open market
- Nov 3, 2025Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
- Jan 12, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Axsome Therapeutics
For Axsome Therapeutics, OQRO holds 12 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AXSM page.
Other recent filings by Herriot Tabuteau, Chief Executive Officer
- SEC Form 4 at Axsome Therapeutics (AXSM)Sep 16, 2025
- SEC Form 4 at Axsome Therapeutics (AXSM)Sep 16, 2025
The full history of Herriot Tabuteau, Chief Executive Officer is on the profile page.
How this filing works
Other disclosures at Axsome Therapeutics
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its AXSM page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data